LifeSci Acquisition Corp. Announces Merger Agreement with Vincera Pharma, Inc. to Create New Publicly Listed Oncology Company Vincera is expected to have approximately $60 million at closing to fund clinical and preclinical development pipeline Stockholders of Vincera post-closing to include Acuta Capital, RTW Investments,...

LifeSci Acquisition Corp. Announces that Common Stock and Warrants Commenced Separate Trading NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition Corp. (NASDAQ: LSAC) (the “Company”) announced today that holders of the Company’s units may elect to separately trade the ordinary...

LifeSci Acquisition Corp. Announces Partial Exercise and Closing of Over-Allotment Option in Public Offering NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition Corp. (NASDAQ: LSACU), a blank check company targeting the biopharma, medical technology, digital health and healthcare services...

LifeSci Acquisition Corp. Announces Closing of $60 Million Initial Public Offering NEW YORK, March 10, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition Corp. (NASDAQ: LSACU), a blank check company targeting the biopharma, medical technology, digital health and healthcare services...

LifeSci Acquisition Corp. Announces Pricing of $60 Million Initial Public Offering NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- LifeSci Acquisition Corp. (NASDAQ: LSACU), a blank check company targeting the biopharma, medical technology, digital health and healthcare services...